International Clinical Trial: SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464756) titled 'SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer' on March 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: The First Affiliated Hospital with Nanjing Medical University

Condition: Gastric Adenocarcinoma

Intervention: Drug: SHR-1701 Drug: apatinib

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 5, 2026

Target Sample Size: 80

To know more, visit https://clinicaltrials.gov/study/N...